Increased behavioral response to dopaminergic stimulation of the subthalamic nucleus after nigrostriatal lesions

Synapse

Volumn 37, Issue 4, 2000, Pages 298-307

  Mehta, Arpesh ^a   Thermos, Kyriaki ^b   Chesselet, Marie Françoise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

6 OHDA; Apomorphine; Dopamine D1 receptor; Dyskinesia; Parkinson disease; Substantia nigra pars compacta; Supersensitivity

Indexed keywords

3 (1 ADAMANTYL) 1 AMINOMETHYL 3,4 DIHYDRO 5,6 DIHYDROXY 1H 2 BENZOPYRAN; APOMORPHINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; CONTROLLED STUDY; DOPAMINE RELEASE; IMAGE ANALYSIS; MALE; MOTOR DYSFUNCTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ADAMANTANE; ANIMALS; APOMORPHINE; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; BENZOPYRANS; CORPUS STRIATUM; DENERVATION; DOPAMINE; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; MALE; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SYMPATHOLYTICS;

EID: 0034666582     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2396(20000915)37:4<298::AID-SYN7>3.0.CO;2-A     Document Type: Article

References (59)

1. Albin RL, Young AB, Penney JB. 1989. The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375.
2. Albin RL, Young AB, Penney JB. 1995. The functional anatomy of disorders of the basal ganglia. Trends Neurosci 18:63-64.
3. Alexander GM, Schwartzman RJ, Grothusen JR, Brainard L, Gordon SW. 1993. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-DOPA treatment. Brain Res 625:276-282.
4. Andersen PH, Jansen JA. 1990. Dopamine receptor agonists: selectivity and dopamine D1 receptor efficacy. Eur J Pharmacol 188: 335-347.
5. Bedard PJ. 1986. Chronic treatment with L-DOPA, but not bromocriptine induced dyskinesias in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 379:294-299.
6. Bergman H, Wichmann T, DeLong MR. 1990. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-1438.
7. Bergman H, Wichmann T, Karmon B, DeLong MR. 1994. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72:507-520.
8. Bischoff S, Heinrich M, Sonntag JM, Krauss J. 1986. The D-1 dopamine receptor antagonist SCH 23390 also interacts potently with brain serotonin (5-HT2) receptors. Eur J Pharmacol 129:367-370.
9. Blanchet P, Bedard PJ, Britton DR, Kebabian JW. 1993. Differential effect of selective D1 and D2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exp Ther 267:274-279.
10. Blanchet PJ, Grondin R, Bedard PJ. 1996. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. Mov Disorders 11:91-94.
11. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. 1990. Differential effects of D1 and D2 agonists in MPTP-treated primates: functional implications for Parkinson's disease. Neurology 40:927-933.
12. Boyson SJ, McGonigle P, Molinoff PB. 1986. Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J Neurosci 6:3177-3188.
13. Campbell GA, Eckardt MJ, Weight FF. 1985. Dopaminergic mechanisms in subthalamic nucleus of rat: analysis using horseradish peroxidase and microiontophoresis. Brain Res 333:261-270.
14. Chase TN, Engber TM, Mouradian MM. 1994. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 44:S15-S18.
15. Chesselet M-F, Delfs JM. 1996. Basal ganglia and movement disorders: an update. Trends Neurosci 19:417-422.
16. Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A. 1988. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093-1102.
17. DeLong MR. 1990. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
18. Domino EF, Sheng J. 1993. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys. J Pharmacol Exp Ther 265:1387-1391.
19. Eberle-Wang K, Lucki I, Chesselet M-F. 1996. A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 72:117-128.
20. Feger J, Hassani OK, Mouroux M. 1997. The subthalamic nucleus and its connections. New electrophysiological and pharmacological data. In: Obeso JA, DeLong MR, Ohye C, Marsden CD, editors. The basal ganglia and new surgical approaches for Parkinson's disease. Adv Neurol 74:31-43.
21. Flores G, Valencia J, Rosales MG, Sierra A, Aceves J. 1993. Appearance of EMG activity and motor asymmetry after unilateral lesions of the dopaminergic innervation to the subthalamic nucleus in the rat. Neurosci Lett 162:153-156.
22. Flores G, Liang JJ, Sierra A, Martinez-Fong D, Quiron R, Aceves J, Srivastava LK. 1999. Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography. Neuroscience 91:549-556.
23. Grondin R, Doan VP, Gregoire L, Bedard PJ. 1999. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 52:771-776.
24. Hamada I, DeLong MR. 1992. Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. J Neurophysiol 68:1850-1858.
25. Hassani OK, Feger J. 1999. Effects of intrasubthalamic injection of dopamine receptor agonists on subthalamic neurons in normal and 6-hydroxydopamine-lesioned rats: an electrophysiological and c-fos study. Neuroscience 92:533-543.
26. Hassani OK, François C, Yelnik J, Feger J. 1997. Evidence for a dopaminergic innervation of the subthalamic nucleus in the rat. Brain Res 749:88-94.
27. Hauber W. 1998. Blockade of subthalamic dopamine D1 receptors elicits akinesia in rats. Neuroreport 9:4115-4118.
28. Herdeen JC. 1999. Tyrosine hydroxylase-immunoreactive elements in the human globus pallid us and subthalamic nucleus. J Comp Neurol 409:400-410.
29. Hutchinson WD, Allan RJ, Opitz H, Levy R, Dostrovsky JO, Lang AE, Lozano AM. 1998. Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol 44: 622-628.
30. Hyland HH, Forman DM. 1957. Prognosis in hemiballismus. Neurology 7:381-391.
31. Izenwasser S, Katz JL. 1993. Differential efficacies of dopamine D1 receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat. Eur J Pharmacol 246:39-44.
32. Kebabian JW, Britton DR, DeNinno MP, Perner R, Smith L, Jenner P, R Schoenleber R, Williams M. 1992. A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 229:203-209.
33. Kelley AE, Delfs JM, Chu B. 1990. Neurotoxicity induced by the D-1 agonist SKF 38393 following microinjection into rat brain. Brain Res 532:342-346.
34. Krack P, Pollack P, Limousin P, Benazzouz A, Deuschl G, Benabid AL. 1999. From off-period dystonia to peak-dose chorea: the clinical spectrum of varying subthalamic activity. Brain 122: 1133-1146.
35. Kreiss DS, Mastropietro CW, Rawji SS, Walters JR. 1997. The response of subthalamic nucleus neurons to dopamine receptor stimulation in a rodent model of Parkinson's disease. J Neurosci 17: 6807-6819.
36. Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, Lang AE. 1998. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 51:850-855.
37. Lappalainen J, Hietala J, Syvalahti E. 1989. Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration. Psychopharmacology 98:472-475.
38. Lavoie B, Smith Y, Parent A. 1989. Dopaminergic innervation of the basal ganglia in the squirrel monkey as revealed by tyrosine hydroxylase immunohistochemistry. J Comp Neurol 289:36-52.
39. Lindvall O, Bjorklund A. 1978. Anatomy of the dopaminergic neuron systems in the rat brain. Adv Biochem Psychopharmacol 19:1-23.
40. Markstein R, Herrling PL. 1978. The effect of bromocriptine on rat striatal adenylate cyclase and rat brain monoamine metabolism. J Neurochem 31:1163-1172.
41. McCreary AC, Handley SL. 1999. The thyrotrophin-releasing hormone analogue MK771 induces tic-like behaviors: the effects of dopamine D1 and D2 receptor antagonists. Eur J Pharmacol 369: 1-9.
42. Mehta A, Yang MI, Chesselet M-F. 1999. Subthalamic GABA A receptors: a functional role and increased sensitivity following ipsilateral dopamine depletion. S Neurosci Abst 25:1159.
43. Mintz I, Hammond C, Feger J. 1986. Excitatory effect of iontophoretically applied dopamine on identified neurons of the rat subthalamic nucleus. Brain Res 375:172-175.
44. Murer MG, Ferrario J, Delfino M, Dziewczapolski G, Gershanik OS, Raisman-Vozari R. 1999. Increased [125I] sulpride binding in the subthalamic nucleus of rats with nigrostriatal lesions. Neuroreport 10:1501-1505.
45. Narang N, Wamsley JK. 1995. Time dependent changes in DA uptake sites, D1 and D2 receptor binding and mRNA after 6-OHDA lesions of the medial forebrain bundle in the rat brain. J Chem Neuroanat 9:41-53.
46. Nobin A, Bjorklund A. 1973. Topography of the monoamine neuron systems in the human brain as revealed in fetuses. Acta Physiol Scand Suppl 388:1-40.
47. Panocka I, Ciccocioppo R, Mosca M, Polidori C, Massi M. 1995. Effects of the dopamine D1 receptor antagonist SCH39166 on the ingestive behavior of the alcohol-preferring rats. Psychopharmacology 120: 227-235.
48. Parent A, Cicchetti F. 1998. The current model of basal ganglia organization under scrutiny [Editorial]. Mov Disord 13:199-202.
49. Parenti M, Gentlemen S, Olianas MC, Neff NH. 1982. The dopamine receptor adenylate cyclase complex: evidence for post recognition site involvement for the development of supersensitivity. Neurochem Res 7:115-124.
50. Parry TJ, Eberle-Wang K, Lucki I, Chesselet M-F. 1994. Dopaminergic stimulation of subthalamic nucleus elicits oral dyskinesia in rats. Exp Neurol 128:181-190.
51. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates, 2nd ed. Australia: Academic Press.
52. Pifl C, Nanoff C, Schingnitz G, Schutz W, Hornykiewicz O. 1992. Sensitization of dopamine-stimulated adenylyl cyclase in the striaturn of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys and patients with idiopathic Parkinson's disease. J Neurochem 58:1997-2004.
53. Ruskin DN, Rawji SS, Walters JR. 1998. Effects of full D1 dopamine receptor agonists on firing rates in the globus pallidus and substantia nigra pars compacta in vivo: tests for D1 receptor selectivity and comparisons to the partial agonist SKF 38393. J Pharmacol Exp Ther 286:272-281.
54. Savasta M, Dubois A, Benavides J, Scatton B. 1988. Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission. Neurosci Lett 85:119-124.
55. Stoessl AJ, Rajakumar N. 1996. Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat. Synapse 24:256-261.
56. Tarsy D, Baldessarini RJ. 1984. Tardive dyskinesia. Annu Rev Med 35:605-623.
57. Ungerstedt U. 1971. Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69-93.
58. Wang JQ, McGinty JF. 1997. The full D1 dopamine receptor agonist SFK-82958 induces neuropeptide mRNA in the normosensitive striatum of rats: regulation of D1/D2 interactions by muscarinic receptors. J Pharmacol Exp Ther 281:972-982.
59. Whittier JR. 1947. Ballism and the subthalamic nucleus (nucleus hypothalamicus, corpus luysi). Arch Neurol Psychiatry 58:672-692.